(NASDAQ: SCPH) Scpharmaceuticals's forecast annual revenue growth rate of 138.89% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.5%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.08%.
Scpharmaceuticals's revenue in 2024 is $13,593,000.On average, 3 Wall Street analysts forecast SCPH's revenue for 2024 to be $1,495,897,429, with the lowest SCPH revenue forecast at $1,406,121,951, and the highest SCPH revenue forecast at $1,644,081,050. On average, 3 Wall Street analysts forecast SCPH's revenue for 2025 to be $3,773,670,772, with the lowest SCPH revenue forecast at $2,953,216,641, and the highest SCPH revenue forecast at $4,856,528,892.
In 2026, SCPH is forecast to generate $6,807,541,127 in revenue, with the lowest revenue forecast at $5,346,868,855 and the highest revenue forecast at $9,258,772,231.